Oncorus (NASDAQ:ONCR) reported quarterly losses of $(0.60) per share. This is a 95.04 percent increase over losses of $(12.09) per share from the same period last year.
Coherus and Junshi Biosciences Late Yesterday Announcd Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ((&ldquo, Coherus&rdquo, , NASDAQ:CHRS), today announced positive interim
